


The Schroder Institutional UK Equity Fund's investment objective is to achieve capital growth through investment in UK equities, although considerable attention will be paid to maintaining a steady growth in income distributions.
| Name | % Net Assets | 
|---|---|
| GlaxoSmithKline | 6.8% | 
| Royal Dutch Shell | 6.0% | 
| Unilever | 5.9% | 
| BG Group | 5.1% | 
| Vodafone | 5.0% | 
| HSBC Holdings | 4.4% | 
| BP | 4.4% | 
| Anglo American | 4.2% | 
| AstraZeneca | 3.7% | 
| Centrica | 3.3% | 
| Key | % Net Assets | 
|---|---|
| 6.8% | |
| 6.0% | |
| 5.9% | |
| 5.1% | |
| 76.2% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 572.40p | 
| Currency | GBP | 
| Change | 0.60p | 
| % | 0.10% | 
| YTD change | 61.90p | 
| YTD % | 12.13% | 
| Fund Inception | 06/05/1997 | 
|---|---|
| Fund Manager | Jeremy Smith | 
| TER | - | 
| Minimum Investment | |
|---|---|
| Initial | £1000000 | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | n/a | 
| Annual Mang't | 0.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.01 | 
| Sharpe ratio | 0.09 | 
You are here: research